Future Research Will Involve Combination Studies for Merkel Cell Carcinoma

Future Research Will Involve Combination Studies for Merkel Cell Carcinoma

User Photo
aacr2017

3 years
2,204 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey explains the impact of data on future research, stating that avelumab is the only FDA approved drug for Merkel Cell Carcinoma, and with moving forward, future research will involve immunotherapy and combination therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Up Next Autoplay
User Photo